Abstract
Introduction. Immune checkpoint (IC) signaling pathways are involved in regulating the functions of T lymphocytes and NK cells, which play a key role in antitumor and antiviral control.
The purpose of our study was to systematically analyze the information presented in current literature on the role of soluble ICs (sICs) in the development of hematological neoplasia.
Material and methods. The review includes data from foreign and domestic articles published in PubMed over the past 15 years, which are devoted to the role of soluble IC molecules in the pathogenesis of hematologic malignancies.
Results. The development of lymphoid and myeloid neoplasia is accompanied by an increase in the level of a number of soluble immunoregulatory molecules (programmed cell death protein 1 (sPD-1) and its ligands sPD-L1 and sPD-L2, cytotoxic lymphocyte antigen 4 (sCTLA-4), T-cell immunoglobulin domain and mucin domain 3 (sTIM-3), costimulatory molecules sCD86, sCD40), which is associated with a poor prognosis, shorter overall and progression-free survival of patients. The established patterns confirm the pathogenetic role of the listed soluble IC molecules in the development of malignant diseases of the blood system, as well as their significance as predictors of response to therapy and risk groups stratification.
Conclusion. The presented analysis demonstrates the significant pathogenetic and prognostic role of sICs in hematological neoplasia of lymphoid and myeloid nature.
Keywords
Authors and affiliations
T.V. Glazanova(1), I.E. Pavlova(1), E.V. Kuzmich(1), N.E. Kushlinskii(2)
1-Russian Research Institute of Hematology and Transfusiology, 2-aya Sovetskaya, 16, Saint-Petersburg, 191024, Russian Federation;
2-N.N. Blokhin Russian Cancer Research Center of the RAMS, Kashirskoe shosse, 24, Moscow, 115478, Russian Federation
References
Рукавицын О.А. Гематология. Национальное руководство, 2-е издание. М.: ГЭОТАР-Медиа, 2024; 920.
[Rukavitsyn O.A. Hematology. National Guide, 2nd edition. GEOTAR-Media, 2024; 920 (in Russian)].
Rau F.C., Dieter J., Luo Z., Priest S., Baumgarth N. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J. Immunol. 2009; 183 (12): 7661–71. DOI: 10.4049/jimmunol.0803783
Hock B., Patton W.N., Budhia S., Mannari D., Roberts P., McKenzie J.L. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia. 2002; 16 (5): 865–73. https://doi.org/10.1038/sj.leu.2402466
Contin C., Pitard V., Delmas Y., Pelletier N., Defrance T., Moreau J.-F., Merville P., Déchanet-Merville J. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immonology. 2003; 110: 131–40. https://doi.org/10.1046/j.1365-2567.2003.01716.x)
Wagner A.H., Klersy A., Sultan C.S., Hecker M. Potential role of soluble CD40 receptor in chronic inflammatory diseases. Biochemical Pharmacology. 2023; 217: 115858. https://doi.org/10.1016/j.bcp.2023.115858
Hock B., McKenzie J.L., Patton N.W., Drayson M., Taylor K., Wakeman C. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer. 2006; 106 (10): 2148–57. DOI: 10.1002/cncr.21816
Landeira-Viñuela A., Arias-Hidalgo C., Juanes-Velasco P., Alcoceba M., Navarro-Bailón A., Pedreira C., Lecrevisse Q., Diaz-Muñoz L., Sánchez-Santos J., Hernández A., Garcia-Vaquero M., Góngora R., De Las Rivas J., González M., Orfao A., Fuentes M. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction. Front. Immunol. 2022; 13. doi.org/10.3389/fimmu.2022.965905
Mortensen J., Hansen I.M., Clausen M.R., Bjerre M., Amore F. Elevated Pre-Therapeutic Serum Levels of Soluble Programmed Death 1 Protein (sPD-1) Identify DLBCL Patients with Adverse Prognostic Features. Blood. 2017; 130 (1): 4148. DOI: 10.1182/blood.V130.Suppl_1.4148.4148
Rossille D., Gressier M., Damotte D., Maucort-Boulch D., Pangault C., Semana G., Le Gouill S., Haioun C., Tarte K., Lamy T., Milpied N., Fest T. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014; 28 (12): 2367–75. DOI: 10.1038/leu.2014.137.
Vajavaara H., Mortensen J.B., Leivonen S.K., Hansen I.M., Ludvigsen M., Holte H., Jørgensen J., Bjerre M., d’Amore F., Leppä S. Soluble PD-1 But not PD-L1 Levels Predict Poor Outcome in Patients With High-Risk Diffuse Large B-Cell Lymphoma. Cancers (Basel). 2021; 13 (3): 398. DOI: 10.3390/cancers13030398
. El-Ghammaz A., Gadallah H.A., Kamal G., Maher M.M., Mohamad M.A. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients. Clin Exp Med. 2018; 18: 505–12. DOI: 10.1007/s10238-018-0506-5
Mortensen J., Monrad I., Enemark M., Ludvigsen M., Kamper P., Bjerre M., d’Amore F. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. Eur J. Haematol. 2021; 107 (1): 81–91. DOI: 10.1111/ejh.13621
Ask E.H., Tschan-Plessl A., Gjerdingen T.J., Sætersmoen M.L., Hoel H.J., Wiiger M.T., Olweus J., Wahlin B., Lingjærde O.C., Horowitz A., Cashen A., Watkins M., Fehniger T., Holte H., Kolstad A., Malmberg K.-J. A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. Clinical and translational article. 2021; 2 (2): 180–95. E5. https://doi.org/10.1016/j.medj.2020.10.006
Iguchi-Manaka A., Okumura G., Kojima H., Cho Y., Hirochika R., Bando H., Sato T., Yoshikawa H., Hara H., Shibuya A., Shibuya K. Increased Soluble CD155 in the Serum of Cancer Patients. PLoS ONE. 2016; 11 (4): e0152982. https://doi.org/10.1371/journal.pone.0152982
. Azzazi M., Hegab H., El-Ghammaz A., Saber H., Afifi Y. Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma. Clin Exp Med. 2022; 22: 173–81. https://doi.org/10.1007/s10238-021-00741-9
Guo X., Wang J., Jin J., Chen H., Zhen Z., Jiang W., Lin T., Huang H., Xia Z., Sun X. High serum level of soluble programmed death ligand 1 is associated with a poor prognosis in Hodgkin lymphoma. Transl Oncol. 2018; 11 (3): 779–85. DOI: 10.1016/j.tranon.2018.03.012
Бессмельцев С.С., Сидоркевич С.В. Федеральное руководство по гематологии. М.: СИМК, 2024; 2: 572.
[Bessmeltsev S.S., Sidorkevich S.V. Federal Guide to Hematology. M: SIMK, 2024; 2: 572 (in Russian)]
Hock B., Drayson M., Patton W.N., Taylor K., Kerr L., McKenzie J.L. Circulating levels and clinical significance of soluble CD86 in myeloma patients. Br. J. Haematol. 2006; 133: 165–72.
. Ishibashi M., Kinoshita R., Inokuchi K., Handa H., Sasaki M., Komatsu N., Imai Y., Hiroike N., Tanaka J., Tanosaki S., Ito S., Sunakawa M., Asayama T., Kuribayashi-hamada Y., Morita R., Tamura H. Serum soluble CD86, still a prognostic factor in the novel agent era in multiple myeloma patients, is produced by myeloma cells with high CD86 variant 3 expression. 2019. Blood. 2019; 134 (1): 436.1 https://doi.org/10.1182/blood-2019-124635
Kinoshita R., Ishibashi M., Handa H., Sasaki M., Imai Y., Tanaka N., Ito S., Sunakawa M., Kaito Y., Asayama T., Komatsu N., Tanaka J., Odajima T., Sugimori H., Yamaguchi H., Inokuchi K., Tamura H. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Experimental Hematology. 2023; 121: 38–47. E2. https://doi.org/10.1016/j.exphem.2023.01.006
Wang L., Wang H., Chen H., Wang W.D., Chen X.Q., Geng Q.R., Xia Z.J., Lu Y. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015; 6 (38): 41228–36. DOI: 10.18632/oncotarget.5682
Huang S.Y., Lin H.H., Lin C.-W., Li C.C., Yao M., Tang J.L., Hou H.A., Tsay W., Chou S.J., Cheng C.L., Tien H.F. Soluble PD-L1: a biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 2016; 7 (38): 62490–502. DOI: 10.18632/oncotarget.11519
Ho A.W., Leleu X., Hatjiharissi E., Tournilhac O., Xu L., O’Connor K., Manning R., Santos D., Chemaly M., Branagan A., Hunter Z., Patterson C., Anderson K., Treon S. A novel functional role for soluble CD27 in the pathogenesis of Waldenstrom’s Macroglobulinemia. Blood. 2005; 106 (11): 4701. https://doi.org/10.1182/blood.V106.11.4701.4701
Hargreaves P., Al-Shamkhani А. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J. Immunol. 2002; 32 (1): 163–73. DOI:10.1002/1521-4141(200201)32:1
Pornkuna R., Nishioka C., Takemoto S. What is the Role of Soluble Cytokine Receptors in Adult T-cell Leukemia/Lymphoma? J Hematol Thrombo Dis. 2014; 2 (5): 1000154. DOI: 10.4172/2329-8790.1000154
. Shigeki T. Possible stimulatory immune checkpoint molecules releasing allows adult T-cell leukemia/lymphoma development. Annals of Oncology. 2016; 27 (7): VII85. https://doi.org/10.1093/annonc/mdw521.046
Wang H., Wang L., Liu W.-J., Xia Z.-J., Huang H.-Q., Jiang W.-Q., Li Z.-M., Lu Y. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. Oncotarget. 2016; 7 (22): 33035–45. DOI: 10.18632/oncotarget.8847
. Ward F., Dahal L.N., Wijesekera S.K., Abdul-Jawad S.K., Kaewarpai T., Xu H., Vickers M.A., Barker R.N.. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J. Immunol. 2013; 43 (5): 1274–85. DOI: 10.1002/eji.201242529
. Ward F., Dahal L.N., Khanolkar R.C., Shankar S.P., Barker R.N. Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy? Immunotherapy. 2014; 6 (10): 1073–84. DOI: 10.2217/imt.14.73
Hayashi H., Chamoto K., Hatae R., Kurosaki T., Togashi Y., Fukuoka K., Goto M., Chiba Y., Tomida S., Ota T., Haratani K., Takahama T., Tanizaki J., Yoshida T., Iwasa T., Tanaka K., Takeda M., Hirano T., Yoshida H., Ozasa H., Sakamori Y., Sakai K., Higuchi K., Uga H., Suminaka C., Hirai T., Nishio K., Nakagawa K., Honjo T. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. The Journal of Clinical Investigation. 2024; 134 (7): e168318. https://doi.org/10.1172/JCI168318
. Sun T., Hu Z., Shen H., Lin D. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res. 2009; 69: 6011–4. DOI: 10.1158/0008-5472.CAN-09-0176
Simone R., Tenca C., Fais F., Luciani M., De Rossi G., Pesce G., Bagnasco M., Saverino D. A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression. PLoS One. 2012; 7 (9): e44654 https://doi.org/10.1371/journal.pone.0044654
. Fais F., Tenca C., Cimino G., Coletti V., Zanardi S., Bagnara D., Saverino D., Zarcone D., De Rossi G., Ciccone E., Grossi C.E. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia. 2005; 19 (4): 551–6. DOI: 10.1038/sj.leu.2403671
Бессмельцев С.С., Сидоркевич С.В. Федеральное руководство по гематологии. М.: СИМК, 2024; 1: 572.
[Bessmeltsev S.S., Sidorkevich S.V. Federal Guide to Hematology. M: SIMK, 2024; 1: 572 (in Russian)]
Kikushige Y., Miyamoto T., Yuda J., Jabbarzadeh-Tabrizi S., Shima T., Takayanagi S., Niiro H., Yurino A., Miyawaki K., Takenaka K., Iwasaki H., Akashi K. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015; 17 (3): 341–52. DOI: 10.1016/j.stem.2015.07.011
36. Bailly C., Thuru X., Goossens L., Goossens J.F. Biochemical Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. Pharmacology. 2023; 209: 115445. DOI: 10.1016/j.bcp.2023.115445
Gonçalves Silva I., Yasinska I., Sakhnevych S., Fiedler W., Wellbrock J., Bardelli M., Varani L., Hussain R., Siligardi G., Ceccone G., Berger S., Ushkaryov Y., Gibbs B., Fasler-Kan E., Sumbayev V. The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017; 22: 44–57. https://doi.org/10.1016/j.ebiom.2017.07.018
Hock B., McKenzie J., Patton W., Haring L., Yang Y., Shen Y. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2003; 98 (8): 1681–8. https://doi.org/10.1002/cncr.11693
Aref S., El Agdar M., El Sebaie A., Abouzeid T., Sabry M., Ibrahim L. Prognostic Value of CD200 Expression and Soluble CTLA-4 Concentrations in Intermediate and High-Risk Myelodysplastic Syndrome Patients. Asian Pacific J. of Cancer Prevention. 2020; 21: 2225–30. DOI: 10.31557/APJCP.2020.21.8.2225